KR100602929B1 - 알파-1 아드레날린성 길항제로서 퀴나졸린 유도체 - Google Patents

알파-1 아드레날린성 길항제로서 퀴나졸린 유도체 Download PDF

Info

Publication number
KR100602929B1
KR100602929B1 KR1020037002933A KR20037002933A KR100602929B1 KR 100602929 B1 KR100602929 B1 KR 100602929B1 KR 1020037002933 A KR1020037002933 A KR 1020037002933A KR 20037002933 A KR20037002933 A KR 20037002933A KR 100602929 B1 KR100602929 B1 KR 100602929B1
Authority
KR
South Korea
Prior art keywords
methyl
amino
phenyl
dimethoxy
quinazolin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020037002933A
Other languages
English (en)
Korean (ko)
Other versions
KR20030022421A (ko
Inventor
베커사이러스케프라
멜빌크리스리챠드
피스터저그롤랜드
장시아오밍
Original Assignee
에프. 호프만-라 로슈 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에프. 호프만-라 로슈 아게 filed Critical 에프. 호프만-라 로슈 아게
Publication of KR20030022421A publication Critical patent/KR20030022421A/ko
Application granted granted Critical
Publication of KR100602929B1 publication Critical patent/KR100602929B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020037002933A 2000-08-31 2001-08-23 알파-1 아드레날린성 길항제로서 퀴나졸린 유도체 Expired - Fee Related KR100602929B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22950300P 2000-08-31 2000-08-31
US60/229,503 2000-08-31
PCT/EP2001/009749 WO2002018348A2 (en) 2000-08-31 2001-08-23 Quinazoline derivatives as alpha-1 adrenergic antagonists

Publications (2)

Publication Number Publication Date
KR20030022421A KR20030022421A (ko) 2003-03-15
KR100602929B1 true KR100602929B1 (ko) 2006-07-20

Family

ID=22861517

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020037002933A Expired - Fee Related KR100602929B1 (ko) 2000-08-31 2001-08-23 알파-1 아드레날린성 길항제로서 퀴나졸린 유도체

Country Status (19)

Country Link
US (1) US6559153B2 (enrdf_load_stackoverflow)
EP (1) EP1315714B1 (enrdf_load_stackoverflow)
JP (1) JP3971299B2 (enrdf_load_stackoverflow)
KR (1) KR100602929B1 (enrdf_load_stackoverflow)
CN (1) CN1308324C (enrdf_load_stackoverflow)
AR (1) AR032475A1 (enrdf_load_stackoverflow)
AT (1) ATE309240T1 (enrdf_load_stackoverflow)
AU (2) AU9378801A (enrdf_load_stackoverflow)
BR (1) BR0113585A (enrdf_load_stackoverflow)
CA (1) CA2420177C (enrdf_load_stackoverflow)
DE (1) DE60114852T2 (enrdf_load_stackoverflow)
ES (1) ES2251512T3 (enrdf_load_stackoverflow)
GT (1) GT200100181A (enrdf_load_stackoverflow)
MX (1) MXPA03001777A (enrdf_load_stackoverflow)
PA (1) PA8527901A1 (enrdf_load_stackoverflow)
PE (1) PE20020407A1 (enrdf_load_stackoverflow)
UY (1) UY26919A1 (enrdf_load_stackoverflow)
WO (1) WO2002018348A2 (enrdf_load_stackoverflow)
ZA (1) ZA200301082B (enrdf_load_stackoverflow)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE341552T1 (de) * 2001-08-10 2006-10-15 Neuro Therapeutics Ltd Derivate morphinähnlicher opioidverbindungen
JP2005521728A (ja) * 2002-04-03 2005-07-21 オリオン コーポレーション ＣＮＳ関連疾患のためのα２−アドレナリン受容体アンタゴニストの使用
TW200403058A (en) * 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
ITMI20030151A1 (it) * 2003-01-30 2004-07-31 Recordati Ind Chimica E Farma Ceutica S P A Uso di antagonisti selettivi del recettore mglu5 per il trattamento di disfunzioni neuromuscolari del tratto urinario inferiore.
DE602004022819D1 (de) * 2003-06-06 2009-10-08 Vertex Pharma Von atp-bindende kassette transportern
HRP20090404T1 (hr) * 2003-07-24 2009-08-31 Euro-Celtique S.A. Spojevi piperidina i farmaceutski sastavi koji ih sadržavaju
WO2006021345A2 (en) * 2004-08-27 2006-03-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with adrenergic alpha-1b receptor (adra1b)
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
US7413607B2 (en) * 2005-03-31 2008-08-19 3M Innovative Properties Company Templated semiconductor particles and methods of making
US7344583B2 (en) * 2005-03-31 2008-03-18 3M Innovative Properties Company Methods of making metal particles within cored dendrimers
ES2334708T3 (es) 2005-05-04 2010-03-15 F. Hoffmann-La Roche Ag (3,4-dihidro-quinazolin-2-il)-(2-ariloxi-etil)-aminas que tienen una actividad sobre el receptor 5-ht.
EP2043655A2 (en) 2006-04-25 2009-04-08 Astex Therapeutics Limited Purine and deazapurine derivatives as pharmaceutical compounds
US7956001B2 (en) * 2006-09-19 2011-06-07 3M Innovative Properties Company Templated metal oxide particles and methods of making
AU2008309383B2 (en) 2007-10-11 2012-04-19 Astrazeneca Ab Pyrrolo [2, 3 -D] pyrimidin derivatives as protein kinase B inhibitors
TW200944526A (en) * 2008-04-22 2009-11-01 Vitae Pharmaceuticals Inc Carbamate and urea inhibitors of 11β-hydroxysteroid dehydrogenase 1
PT2694056T (pt) 2011-04-01 2019-11-20 Astrazeneca Ab Tratamento terapêutico
SI2785349T2 (sl) 2011-11-30 2023-01-31 Astrazeneca Ab Kombinirano zdravljenje raka
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms
JP7376358B2 (ja) * 2017-03-12 2023-11-08 ワン，シャオドン オピオイド受容体調節因子としての多環式アミン
WO2019088095A1 (ja) * 2017-11-02 2019-05-09 国立大学法人九州大学 鎮痛剤及びその使用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2232138A1 (en) 1995-09-29 1997-04-03 William C. Lumma Alpha 1b adrenergic receptor antagonists
NZ325248A (en) * 1995-12-23 1999-09-29 Pfizer Res & Dev Quinoline and quinazoline compounds useful in therapy
GB9700504D0 (en) 1997-01-11 1997-02-26 Pfizer Ltd Pharmaceutical compounds
US6355641B1 (en) 1999-03-17 2002-03-12 Syntex (U.S.A.) Llc Oxazolone derivatives and uses thereof

Also Published As

Publication number Publication date
EP1315714B1 (en) 2005-11-09
BR0113585A (pt) 2003-07-29
ES2251512T3 (es) 2006-05-01
ATE309240T1 (de) 2005-11-15
PA8527901A1 (es) 2002-07-30
PE20020407A1 (es) 2002-05-21
UY26919A1 (es) 2002-02-28
ZA200301082B (en) 2004-05-07
CA2420177C (en) 2008-07-08
AU9378801A (en) 2002-03-13
AR032475A1 (es) 2003-11-12
EP1315714A2 (en) 2003-06-04
DE60114852T2 (de) 2006-07-27
WO2002018348A3 (en) 2002-07-11
JP3971299B2 (ja) 2007-09-05
WO2002018348A2 (en) 2002-03-07
US20020045614A1 (en) 2002-04-18
DE60114852D1 (de) 2005-12-15
KR20030022421A (ko) 2003-03-15
CN1308324C (zh) 2007-04-04
CN1545510A (zh) 2004-11-10
JP2004507527A (ja) 2004-03-11
MXPA03001777A (es) 2003-06-04
US6559153B2 (en) 2003-05-06
AU2001293788B2 (en) 2007-10-11
CA2420177A1 (en) 2002-03-07
GT200100181A (es) 2002-05-23

Similar Documents

Publication Publication Date Title
KR100602929B1 (ko) 알파-1 아드레날린성 길항제로서 퀴나졸린 유도체
AU2001260310B2 (en) Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists
KR100413150B1 (ko) 5-에이치티4 수용체 길항제로서의 디하이드로벤조디옥신 카복스아미드 및 케톤 유도체
KR100544000B1 (ko) 치환된 1-아미노알킬-락탐 및 무스카린성 수용체길항제로서의 용도
AU2001293788A1 (en) Quinazoline derivatives as alpha-1 adrenergic antagonists
US6319920B1 (en) 2-arylethyl-(piperidin-4-ylmethyl)amine derivatives
KR100686757B1 (ko) 2,4-치환된 인돌 및 그의 5-ｈｔ6 조절제로서 용도
KR100687992B1 (ko) 무스카린 수용체 길항제로서 4-피페리딘일 알킬아민 유도체
KR100668231B1 (ko) 무스카린 수용체 길항제로서의 아미노테트랄린 유도체
JP2009513504A (ja) ５−置換キナゾリノン誘導体
US6355641B1 (en) Oxazolone derivatives and uses thereof
SK137597A3 (en) 1-£'omega'-(3,4-dihydro-2-naphthalenyl)alkyl| cyclic amine derivatives, process for producing the same, and medicinal composition containing the same
CZ20003121A3 (cs) 2-Arylethyl-(piperidin-4-ylmethyl)aminové deriváty jako antagonisty muskarinového receptoru

Legal Events

Date Code Title Description
A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20090713

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20090713

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000